达普司他治疗促红细胞生成素低反应患者的探索性研究
这项2a期、探索性、多中心、单臂研究评估达普司他在16周内对血液透析且促红细胞生成素抵抗指数高的贫血患者提升或维持血红蛋白至目标范围(10.0-11.5 g/dl)的能力。60例筛查者中15例入组,7例(47%)完成16周治疗;
要点
- 达普司他在29%的促红细胞生成素低反应血液透析患者中使血红蛋白升高>1 g/dl。
- 研究期间未发现新的安全性信号,但不良事件发生率高达93%。
- 达普司他对铁代谢和利用指标影响极小。
核心结论
- 达普司他在29%的慢性促红细胞生成素低反应受试者中使血红蛋白浓度升高至目标范围内。
- 这项短期探索性研究未发现新的安全性问题。
研究设计与样本
- 2a期、探索性、多中心、单臂研究,评估达普司他在血液透析且促红细胞生成素抵抗指数高的贫血患者中的疗效和安全性。
- 筛查60例,入组15例,7例(47%)完成16周治疗;所有受试者初始接受口服达普司他12 mg每日一次。
主要发现
- 第16周时,7例受试者中2例(29%)血红蛋白较基线增加>1 g/dl。
- 达普司他对铁代谢和利用标志物的影响极小。
关键数值与推荐
- 所有入组受试者符合慢性重组人促红细胞生成素低反应标准,即基于至少12周的患者血红蛋白与阿法依泊汀连续分层计算的促红细胞生成素抵抗指数。
- 符合条件的成人受试者接受稳定的血液透析方案,每周3至4次。
- 血红蛋白目标范围为10.0-11.5 g/dl。
临床怎么用
- 对于血液透析且促红细胞生成素低反应的贫血患者,达普司他可能作为改善血红蛋白的探索性治疗选择。
- 治疗期间需监测血红蛋白和铁代谢指标,并关注恶心、肺炎、胸腔积液和尿路感染等不良事件。
局限性
- 探索性、单臂、小样本研究,仅15例入组且7例完成治疗,结果解释需谨慎。
- 研究持续时间短(16周),长期疗效和安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hyporesponsiveness to recombinant human erythropoietin (rhEPO) is a major problem affecting some patients with chronic kidney disease (CKD), predominantly those on hemodialysis (HD). Daprodustat (GSK1278863) is a hypoxia-inducible factor prolyl hydroxylase inhibitor that is being investigated as a treatment for anemia of CKD. METHODS: This phase 2a, exploratory, multicenter, single-arm study assessed the ability of daprodustat to increase or maintain hemoglobin concentrations within the target range (10.0-11.5 g/dl) over 16 weeks in subjects with anemia who were on HD and who had a high erythropoietin resistance index (ERI). All included subjects met the criteria for chronic rhEPO hyporesponsiveness (i.e., an ERI based on a series of contiguous strata of patients' hemoglobin-by-epoetin alfa for a minimum of 12 weeks). Eligible adults were on a stable HD regimen 3 to 4 times per week. Markers of iron utilization and safety were also assessed. All subjects initially received oral daprodustat 12 mg once daily. RESULTS: Of the 60 participants screened, 15 were enrolled, and 7 (47%) completed 16 weeks of treatment. At week 16, 2 of 7 subjects (29%) had >1 g/dl increases in hemoglobin from baseline. Daprodustat had minimal effects on markers of iron metabolism and utilization. Fourteen subjects (93%) experienced ≥1 adverse event (AE). The most common AEs included nausea, pneumonia, pleural effusion, and urinary tract infection. The majority of on-therapy AEs were mild or moderate in intensity. CONCLUSION: Daprodustat increased hemoglobin concentrations within the target range in 29% of chronic rhEPO-hyporesponsive subjects. No new safety concerns were identified in this short exploratory study.
引用
- Cizman B, Sykes AP, Paul G, et al. An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects. Kidney Int Rep. 2018. PMID: 29989040. doi:10.1016/j.ekir.2018.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。